The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

NCT03542110 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

46

Enrollment

OTHER

Sponsor class

Stopped Withdrawal of medication and funding support by Sponsor

Conditions

Saphenous Vein Graft Atherosclerosis

Interventions

DRUG: Alirocumab 150 MG/ML subcutaneous injection
DRUG: Matching Placebo subcutaneous injection

Sponsor

Minneapolis Heart Institute Foundation

Collaborators

[object Object]